<<專任教師>> English

  蘇剛毅老師
職稱

 

 

Su

國立台灣大學醫學院醫學檢驗暨生物技術學系
助理教授
國立台灣大學醫學院附設醫院
兼任醫事檢驗師
國立台灣大學基因體暨系統生物學學位學程
助理教授
 
學歷
國立台灣大學醫學院分子醫學研究所 博士
國立台灣大學醫學院醫事技術學研究所 碩士
國立台灣大學醫學院醫事技術學系 學士
美國專案管理學院專案管理師
 
經歷
國立台灣大學基因體醫學研究中心 助理研究員
中央研究院統計科學研究所 博士後研究學者
國立台灣大學醫學院內科 博士後研究員
國立台灣大學醫學院醫事技術學系 博士後研究員
 
研究專長
臨床生化學、醫學分子檢驗學、癌症生物學、生物晶片
 
聯絡方式
辦公室:
台北市中正區常德街一號 檢驗大樓五樓 R522
台北市中正區徐州路二號 基因體醫學研究中心 微陣列核心實驗室
實驗室:
台北市中正區常德街一號 檢驗大樓五樓 R521-1
台北市中正區徐州路二號 基因體醫學研究中心 微陣列核心實驗室
電話:
辦公室 02-23123456轉 88697、66910
實驗室 02-23123456轉 66923、88695
E-mail:
suky@ntu.edu.tw
 
榮譽獲獎
2007 台大醫學院優秀研究生論文獎
2009 台灣基因體暨遺傳學會口頭論文獎
2013-2015 科技部延攬優秀特殊人才獎
2014 Travel Grant Award, 73rd Annual Meeting of JAPAN Cancer Association
2015 國立台灣大學教學優良教師
2016 Travel Grant Award, 75rd Annual Meeting of JAPAN Cancer Association
2016 國立台灣大學教學優良教師
2016 Travel Grant Award, 2016 APFCB 亞太臨床生化學會 Congress
2016-2019 科技部優秀年輕學者補助
2016財團法人肺病防治基金會學術表現優良獎
2017國立台灣大學教學傑出教師
 
研究主題
本實驗室主要的研究方向為落實轉譯醫學提供個人化醫療之策略。重點領域包括: 

1. 建立分子檢驗平台

    為因應個人化醫療時代,建立高敏感度與高特異性基因突變檢測平台,提供臨床病人進行治療前篩選,接受最有效且適當的投藥,已是刻不容緩的議題。我們已利用核酸質譜儀建立多基因檢測套組,鑑定臨床癌症病人重要基因突變,篩選出適合接受標靶藥物治療之病人,有效預測用藥反應與存活期。在將來的研究中,將持續不斷發展各類基因檢測,供各醫學領域需求,包括:臨床生化檢測、感染症、心血管疾病等。

2. 建立人類疾病動物模型

    為因應後基因體時代以及未來新藥開發,疾病動物模型建立為不可或缺之臨床前試驗重要工具,過去研究成果,本實驗室陸續建立及引進相關基因工程改造小鼠,包括: a.誘發性肺癌小鼠模型-經誘發表現表皮生長因子受器後,可自發性產生肺腺癌,除了可以提供癌症發生特異性訊息傳遞外,更可以做為潛力抗癌藥物驗證模型。b.腫瘤轉移抑制基因剔除小鼠-此基因缺損小鼠會因為肝臟內質網壓力失調造成脂肪肝,且對於環境壓力緩解以及肝臟解毒功能皆有異於野生型小鼠,將來可以做為肝臟疾病治療模型。c.微核糖核酸基因剔除小鼠-發現小鼠缺乏特定微核糖核酸後表現出心臟方面相關異常表現型,具有成為心血管疾病之動物模型。除了基因工程改造動物模型外,因應生活壓力造成之精神異常疾病已日益受到重視,在過去成果中亦建立模擬人類生活壓力造成之精神疾病動物模型,且利用微陣列相關平台,分析參與疾病發生的重要相關訊息傳遞。

 
期刊論文
  1. Su KY, Yan BS, Chiu HC, Yu CJ, Chang SY, Jou R, Liu JL, Hsueh PR, Yu SL. Rapid Sputum Multiplex Detection of the M. tuberculosis Complex (MTBC) and Resistance Mutations for Eight Antibiotics by Nucleotide MALDI-TOF MS. Sci Rep. 2017 Jan 30;7:41486. doi: 10.1038/srep41486.
  2. Pan SH, Su KY, Spiessens B, Kusuma N, Delahaye NF, Gruselle O, Myo A, Creus Ad, Louahed J, Chang GC, Yu SL, Yang PC. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients. Asia-Pacific Journal of Clinical Oncology. Jul 2016. DOI: 10.1111/ajoc.12586
  3. Su KY, Kao JT, Ho BC, Chen HY, Chang GC, Ho CC, Yu SL. Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinica Practice. Scientific Reports 2016 Aug 2;6:30944. doi: 10.1038/srep30944.
  4. Huang P, Cheng CL, Chang YH, Liu CH, Hsu YC, Chen JS, Chang GC, Ho BC, Su KY, Chen HY, Yu SL. Molecular gene signature and prognosis of non-small cell lung cancer. Oncotarget.  2016 Jul 16. doi: 10.18632/oncotarget.10622. [Epub ahead of print]
  5. Hsu KH, Tseng JS, Wang CL, Yang TY, Tseng CH, Chen HY, Chen KC, Tsai CR, Yang CT, Yu SL, Su KY, Yu CJ, Ho CC, Hsia TC, Wu MF, Chiu KL, Liu CM, Yang PC, Chen JJW, Chang GC. Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget. 2016 Jul 19. doi: 10.18632/oncotarget.10715. [Epub ahead of print]
  6. Hsiao YJ, Su KY, Hsu YC, Chang GC, Chen JS, Chen HY, Hong QS, Hsu SC, Kang PH, Hsu CY, Ho BC, Yang PC, Yu SL. SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung cancer. Oncotarget 2016 Jun 15. doi: 10.18632/oncotarget.10088. [Epub ahead of print]
  7. Tseng JS*, Su KY*, Yang TY, Chen KC, Hsu KH, Chen HY, Tsai CR, Yu SL, Chang GC. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFRTKI: Focus on rebiopsy timing and long-term existence of T790M. Oncotarget 2016 Jun 30. doi: 10.18632/oncotarget.10351. [Epub ahead of print] (*Equal First Author)
  8. Sun LP, Xu X, Hwang HH, Wang X, Su KY*, Chen YL*. Dichlormethane extracts of Propolis protect cell from oxygen-glucose deprivation induced oxidative stress via reducing apoptosis . Food and Nutrition Research. 2016 Jun 20;60:30081. doi: 10.3402/fnr.v60.30081. eCollection 2016. (*Equal Corresponding Author)
  9. Chen CH, Chang WH,Su KY, Ku WH, Chang GC, Hong QS, Hsiao YJ, Chen HC, CHen HY, Wu R, Yang PC, Chen JJW, Yu SL. HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene. 2016 Apr 11; doi: 10.1037/onc.2016.106
  10. Chang WH, Ho BC, Hsiao YJ, Chen JS, Yeh CH, Chen HY, Chang GC, Yu SL, Su KY*. JAG1 is associated with poor survival through inducing metastasis in lung cancer. Plos One. 2016 Mar 1;11(3):e0150355. doi: 10.1371/journal.pone.0150355. eCollection 2016. (*Corresponding Author)
  11. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M Mutation and Common Activating Mutations in Pretreatment Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis. In Press. Lung Cancer. 2016 Feb. DOI: http://dx.doi.org/doi:10.1016/j.lungcan.2016.01.019
  12. Tseng CH, Chen KC, Hsu KH, Tseng JS, Ho CC, Hsia TC, Su KY, Wu MF, Chiu KL, Liu CM, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Yang TY, Chang GC. EGFR mutation and lobar location of lung adenocarcinoma. Carcinogenesis.2016 Feb;37(2):157-62. doi: 10.1093/carcin/bgv168. Epub 2015 Dec 8.
  13. Huang YH, Hsu KH, Tseng JS, Chen KC, Su KY, Chen HY, Chang CS, Chen JJ, Yu SL, Chen HW, Yang TY, Chang GC. Prediction of contralateral upper lung metastasis in upper lobe lung adenocarcinoma patients. J Thorac Dis. 2016 Jan;8(1):86-92. doi: 10.3978/j.issn.2072-1439.2016.01.24.
  14. Huang KY, Kao SH, Wang WL, Chen CY, Hsiao TH, Salunke SB, Chen JJW, Su KY, Yang SC, Hong TM, Chen CS, Yang PC. Small-Molecule, T315, Promotes CBL-Dependent Degradation of EGFR via Y1045 Autophosphorylation. Am J Respir Crit Care Med. First publish online, 19 Nov, 2015. DOI: 10.1164/rccm.201502-0250OC.
  15. Chen HY, Yu SL, Ho BC, Su KY, Hsu YC, Chang CS, Li YC, Yang SY, Hsu PY, Ho H, Chang YH, Chen CY, Yang HI, Hsu CP, Yang TY, Chen KC, Hsu KH, Tseng JS, Hsia JY, Chuang CY, Yuan S, Lee MH, Liu CH, Wu GI, Hsiung CA, Chen YM, Wang CL, Huang MS, Yu CJ, Chen KY, Tsai YH, Su WC, Chen HW, Chen JJ, Chen CJ, Chang GC, Yang PC, Li KC. R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. J Clin Oncol. 2015 Jun 8. pii: JCO.2014.59.3590. [Epub ahead of print]
  16. Wang CC, Su KY, Chen HY, Chang SY, Shen CF, Hsieh CH, Hong QS, Chiang CC, Chang GC, Yu SL, Chen JJ. HOXA5 Inhibits Metastasis via Regulating Cytoskeletal Remodelling and Associates with Prolonged Survival in Non-Small-Cell Lung Carcinoma. PLoS One. 2015 Apr 14;10(4):e0124191. doi: 10.1371/journal.pone.0124191. eCollection 2015.
  17. Hsu KH, Ho CC, Hsia TC, Tseng JS, Su KY, Wu MF, Chiu KL, Yang TY, Chen KC, Ooi H, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Chang GC. Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in taiwan. PLoS One. 2015 Mar 19;10(3):e0120852. doi: 10.1371/journal.pone.0120852. eCollection 2015.
  18. Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Chen JJ, Chang GC. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2014 Dec 15. [ahead of print]
  19. 蘇剛毅、何肇基、俞松良、施金元、楊泮池 肺癌關鍵突變基因之意義與檢測。特輯 台灣醫學 Formosan J Med 2014; 18: 644-653. DOI:10.6320/FJM.2014.18(6).04
  20. Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, Tsai CR, Chen KC, Hsu KH, Tsai MH, Yu SL, Su KY, Wu CW, Yang CT, Chen YM, Chang GC. Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS One. 2014 Sep 12;9(9):e107160. doi: 10.1371/journal.pone.0107160. eCollection 2014.
  21. Chen CC, Chen HY, Su KY, Hong QS, Yan BS, Chen CH, Pan SH, Chang YL, Wang CJ, Hung PF, Yuan SS, Chang GC, Chen JJ, Yang PC, Yang YC, Yu SL. Shisa3 Associated with Prolonged Survival through Promoting β-catenin Degradation in Lung Cancer. Am J Respir Crit Care Med. 2014 Jul 18. [Epub ahead of print]
  22. Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJW, Chen HY, Chang GC. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma. OncoTargets and Therapy. 3 May, 2014:7 1-7
  23. Su KY, Hsieh CY, Chen YW, Chuang CT, Chen CT, Chen YL.
    Taiwanese Green Propolis and Propolin G protect liver from the pathogenesis of fibrosis via eliminating TGF-β induced Smad2/3 phosphorylation. Journal of Agricultural and Food Chemistry. 2014 Mar 13. [Epub ahead of print]
  24. Su KY*, Yu CY*, Chen YW, Huang YT, Hua KF, Chung CT, Chen CT, Wu HF, Chen YL. Rutin, a Flavonoid and Principal Component of Saussurea Involucrata, Attenuates Physical Fatigue in a Forced Swimming Mouse Model. International Journal of Medical Science. 2014  (equal first author)
  25. Su KY, Yu CY, Chen YP, Hua KF, Chen YL. 3,4-Dihydroxytoluene, a metabolite of rutin, inhibits inflammatory responses in lipopolysaccharide-activated macrophages by reducing the activation of NF-kappaB signaling. BMC Complementary and Alternative Medicine. 2014, 14:21 DOI: 10.1186/1472-6882-14-21
  26. Yu CY, Su KY, Lee PL, Jhan JY, Tsao PH, Chan DC, Chen  YL. Potential Therapeutic Role of Hispidulin in Gastric Cancer through Induction of Apoptosis via NAG-1 Signaling. Evid Based Complement Alternat Med. 2013, Article ID 518301, 12 pages, http://dx.doi.org/10.1155/2013/518301
  27. Chen YT, Tsai MS, Yang TL, Ku AT, Huang KH, Huang CY, Chou FJ, Hsigng HH, Hong JB, Yen ST, Wang WL, Lin CC, Hsu YC, Su KY, Su IC, Jang CW, Behringer RR, Favaro R, Nicolis SK, Chien CL, Wu YM, Lin SW, Yu IS. R26R-GR: a Cre-activable Dual Fluorescent Protein Reporter Mouse. Plos one. 2012;7(9):e46171. doi: 10.1371/journal.pone.0046171. Epub 2012 Sep 25
  28. Ou JP, Lin HY, Su KY, Yu SL, Tseng IH, Chen CJ, Hsu HC, Chan DC, Chen YL. Potential Therapeutic role of Z-Isochaihulactone in Lung Cancer Through Inductio of Apoptosis via Notch Signaling. Evid Based Complement Alternat Med. 2012;2012:809204. doi: 10.1155/2012/809204. Epub 2012 Sep 24.
  29. Yang YC, Lin HY, Su KY, Chen CH, Yu YL, Lin CC, Yu SL, Yan HY, Su KJ, Chen YL. Rutin, a flavonoid that is a main component of Saussurea involucrata attenuates the senescence effect in D-galactose aging mouse model. Evid Based Complement Alternat Med. 2012;2012:980276. doi: 10.1155/2012/980276. Epub 2012 Aug 16.
  30. Hsu YC, Huang HP, Yu IS, Su KY, Lin SR, Lin WC, Wu HL, Shi GY, Tao MH, Kao CH, Wu YM, Martin PE, Lin SY, Yang PC, Lin SW. Serine protease hepsin regulates hepatocyte size and hemodynamic retention of tumor cells via hepatocyte growth factor signaling. Hepatology. 2012 Apr 13. doi: 10.1002/hep.25773. [Epub ahead of print]
  31. Su KY, Chen HY, Li KC, Kuo ML, Yang James CH, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Pre-treatment EGFR T790M Mutation Predicts Shorter EGFR-TKI Response Duration in Non-small-cell Lung Cancer Patients. J Clin Oncol. 2012 Feb 1;30(4):433-40. Epub 2012 Jan 3.
  32. Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, Yang PC. Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma With EGFR-Activating Mutations. J Clin Oncol. 2011 Sep 1;29(25):3435-42. Epub 2011 Aug 1.
  33. Tsai TH*, Su KY*, Wu SG, Chang YL, Luo SC, Jan IS, Yu CJ, Yu SL, Shih JY, Yang PC. RNA is Favorable for Analyzing EGFR Mutations in Malignant Pleural Effusion of Lung Cancer. Eur Respir J. 2012 Mar;39(3):677-84. Epub 2011 Jun 30. (equal first author)
  34. Ho BC, Yu SL, Chen JJ, Chang SY, Yan BS, Hong QS, Singh S, Kao CL, Chen HY, Su KY, Li KC, Cheng CL, Cheng HW, Lee JY, Lee CN, Yang PC. Enterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E. Cell Host Microbe. 2011 Jan 20;9(1):58-69.
  35. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1071-9. Epub 2010 Oct 29.
  36. Su KY, Chien WL, Fu WM, Yu IS, Huang HP, Huang PH, Lin SR, Shih JY, Lin YL, Hsueh YP, Yang PC, Lin SW. Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory. J Neurosci. 2007 Mar 7;27(10):2513-24.
  37. Chen CH, Su KY, Tao MH, Lin SW, Su YH, Tsai YC, Cheng KC, Jeng YM, Sheu JC. Decreased expressions of hepsin in human hepatocellular carcinomas. Liver Int. 2006 Sep;26(7):774-80. (SCI)

 

研討會論文
  1. KY Su, JT Kao, BC Ho, HY, Chen, GC Chang, CC Ho, SL Yu. The Model of Implementation and Quality Control for Molecular Diagnosis in Taiwan Lung Cancer Pharmacogenomic Routine Practice. 14th Annual Congress of APFCB (Asia Pacific Federation of Clinical Biochemistry), 2016 Nov 26-29. Taipei, Taiwan. (Travel Grant Award) (Travel Grant Award)
  2. KY Su, HY Chen, GC Chang, PC Yang, SL Yu. Application of Nucleotide Mass Spectrometry for Lung Cancer Precision Medicine from Solid to Liquid Sample. The 75rd Annual Meeting of the Japanese Cancer Association, 2016 Oct 6-8. Pacifico Yokohama, Yokohama, JAPAN (Invited Speaker) (Travel Grant Award)
  3. KY Su, JT Kao, HY Chen, YL Chen, CC Wang, GC Chang, CC Ho, SL Yu. Routine pharmacogenomic testing of lung cancer in Taiwan. J Clin Oncol 34, 2016 (suppl; abstr e13126) 49th ASCO Annual Meeting-American Society of Clinical Oncology, 2015 May 29-Jun 3. Chicago, IL, U.S.A.
  4. YJ Hsiao, KY Su, HY Chen, SL Yu. Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. 48th ASCO Annual Meeting-American Society of Clinical Oncology, 2015 May 29-Jun 3. Chicago, IL, U.S.A. J Clin Oncol 33, 2015 (suppl; abstr e19148)
  5. HF Wu, YL Chen, KY Su, A New Hippocampal Pathway: CRMP-1 Regulates Consolidation of Contextual Fear Memory. International Journal of Arts & Sciences (IJAS) Conference, 2015 Apr 13-16. Paris, France
  6. KY Su, Impromement of Lung Cancer Personalized Therapy by Molecular Diagnostics and Disease Animal Model. 62th Meeting of The Chinese Society of Comparative Pathology. 2014 Nov 9. Taoyuan, Taiwan. (Invited keynote speaker)
  7. KY Su, CC Chiang, SH Pan, HY Chen, JJW Chen, SL Yu, Suppression of Microphthalamia-associated Transcription Factor Enhances Tumor Malignancy in Lung Cancer. The 73rd Annual Meeting of the Japanese Cancer Association, 2014 Sep 25-27. Pacifico Yokohama, Yokohama, JAPAN (Invited Speaker) (Travel Grant Award)
  8. KY Su and SL Yu, Traceability of Molecular Diagnostics, JCTLM (Joint Committee of Traceability in Laboratory Medicine) Members and Stakeholders Meeting, 2013 Dec 4-5. Paris, France.
  9. KY Su, The Trend of Molecular Diagnostics in Cancer Personalized Therapy, 13th Annual Congress of APFCB (Asia Pacific Federation of Clinical Biochemistry), 2013 Oct 27-30. Bali, Indonesia. (Invited Speaker)
  10. KY Su, iRICE International Cooperation, Annual Meeting for Gap Academic Conference of MD Anderson Cancer Center, 2013 April 3-5, Houston, TX, U.S.A
  11. KY Su, SL Yu. Personalized molecular testing for therapeutic guidance in Taiwan. 47th ASCO Annual Meeting-American Society of Clinical Oncology, 2013 May 31-Jun 4. Chicago, IL, U.S.A. Journal of Clinical Oncology 2013 31:15 SUPPL. 1 
  12. KY Su, YL Chen, BS Yan, PR Hsueh, CJ Yu, HY Chen, PC Yang, SL Yu. High Sensitive Multiplex MALDI-TOF Mass Spectrometry for M. tuberculosis Identification and Drug Resistance Prediction. 2012 Keystone Symposia Conference. E1: Drug Resistance and Persistence in Tuberculosis. 2012 May 13-18. Kampala, Uganda
  13. KY Su, MH Chien, YM Wu, JJ.W. Chen, SL Yu, PC Yang. Mice Deficient in HLJ1 Exhibit Fatty Liver and Impaired Lipid Metabolism – An Animal Model for Steatohepatitis 47th The International Liver CongressTM 2012 April 18-22. Barcelona, Spain
  14. Su KY, Lai YC, Yang PC, Yu SL. The Oncogenic Role of MALL in NSCLC-MALL Promotes Cancer Invasion. AACR 101th annual meeting 2010 April 17-21. Washington, DC
  15. Su KY, Shih JY, Kao HC, Hsu CC, Lin CY, Li KC, Yu SL, Yang PC. Detection of EGFR Mutation by High Sensitive MALDI-TOF MS for Predicting EGFR-TKIs Response and Treatment Outcome of Stage IIIB/IV Patients. AACR-JCA Joint Conference 2010 February 5-9. Hawaii.
  16. Su KY, Yang TH, Hsu CC, Li KC, Chen JJW, Yang PC, Yu SL, Chen HY. Functional Characterization of a Sperm Protein, SPANXA1, in Lung Cancer Progression. AACR 100th annual meeting 2009 April 18-22. Denver.
  17. Su KY, Su YH, Hsu YC, Chang JS, Shi GY, Wu HL and Lin SW. Hepsin, a gene related to hemostasis, inhibit tumor metastasis in a transgenic mouse model. The 4th Asia-Pacific Congress on thrombosis and hemostasis 2006
  18. Su KY, Yu IS, Lin SR, Huang HY, Huang PH, Hong G, and Lin SW. (2003). Consequences of expression of hepsin in murine vascular systems. Abstract. The XIX Congress of the International Society on Thrombosis and Haemostasis. Birminham, UK. July, 2003.
  19. Su KY, Yu IS, Huang HY, Huang PH, Hong G, Lin SW. (2003) Consequences ofexpressing a prostate cancer-related gene, hepsin, in murine vasculature. Mouse Model of Cancer (Special Conference of American Association for Cancer Research) Feb 5-10 2003 Orlando, USA
  20. Su KY, Hyang HY, Yu IS, Huang PH, Hong G, Lin SW. (2002) Study of hepsin, a gene related to haemostasis, by transgenic technology. Centre of Modeling Human Disease (CMHD) Symposium : Functional Analysis of Mouse Genome Dec 12 2002 Toronto, Canada (Invited Speaker)
  21. Su KY, Huang HY, Yu IS, Huang PH, Hong G, Lin SW. Overexpression of hepsin in vascular endothelial cells results in embryonic lethality. XVIII Congress The International Society on Thrombosis and Haemostasis. 2001. July 6-12, Paris, France
專利
分枝桿菌的鑒定與抗藥性判定的快速篩檢方法 (美國暫時性專利, US/61/752102)